MLLCF MOLECULAR PARTNERS AG
- 3.800
- 0.0000.00%
MOLECULAR PARTNERS AG News
Molecular Partners Announces Publication in Cancer Immunology Research of Preclinical Data Supporting MP0533's Proposed Mechanism of Action
Press Release: Molecular Partners Announces All Board Proposals Approved at the Annual General Meeting
Molecular Partners Announces All Board Proposals Approved at the Annual General Meeting ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., April 17, 2024 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX
Press Release: Molecular Partners Publishes Invitation to Annual General Meeting 2024
Molecular Partners Publishes Invitation to Annual General Meeting 2024 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 26, 2024 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: M
Molecular Partners AG: Strong Financials & Promising Pipeline Justify Buy Rating
Molecular Partners To Hold Conference Call to Discuss Fourth Quarter and Full Year 2023 Results and Announces Upcoming Investor Presentations
Retail Investors Account for 43% of Molecular Partners AG's (VTX:MOLN) Ownership, While Hedge Funds Account for 33%
Getting In Cheap On Molecular Partners AG (VTX:MOLN) Is Unlikely
Molecular Partners AG (NASDAQ:MOLN) Q4 2022 Earnings Call Transcript
Tang Capital Management LLC Buys Shares of 15,681 Molecular Partners AG (NASDAQ:MOLN)
Tang Capital Management LLC bought a new stake in shares of Molecular Partners AG (NASDAQ:MOLN – Get Rating) in the 3rd quarter, HoldingsChannel.com reports. The institutional investor bought 15,681
Molecular Partners Starts Early-stage Study of Blood Cancer Drug MP0533
Hedge Funds Own 28% of Molecular Partners AG (VTX:MOLN) Shares but Individual Investors Control 41% of the Company
Molecular Partners AG (NASDAQ:MOLN) Short Interest Update
Molecular Partners AG (NASDAQ:MOLN – Get Rating) was the target of a large drop in short interest in the month of December. As of December 15th, there was short interest totalling 11,700 shares, a d
Molecular Partners AG (OTCMKTS:MLLCF) Sees Significant Decline in Short Interest
Molecular Partners AG (OTCMKTS:MLLCF – Get Rating) was the target of a significant decrease in short interest during the month of December. As of December 15th, there was short interest totalling 113
Molecular Partners AG (OTCMKTS:MLLCF) Short Interest Update
Molecular Partners AG (OTCMKTS:MLLCF – Get Rating) was the recipient of a significant decline in short interest in November. As of November 30th, there was short interest totalling 162,100 shares, a
Molecular Partners AG's (VTX:MOLN) Stock's On An Uptrend: Are Strong Financials Guiding The Market?
FY2023 EPS Estimates for Molecular Partners AG (NASDAQ:MOLN) Cut by Analyst
Molecular Partners AG (NASDAQ:MOLN – Get Rating) – Equities researchers at SVB Leerink decreased their FY2023 earnings per share estimates for shares of Molecular Partners in a research note issued
FY2022 EPS Estimates for Molecular Partners AG (NASDAQ:MOLN) Raised by SVB Leerink
Molecular Partners AG (NASDAQ:MOLN – Get Rating) – Equities researchers at SVB Leerink raised their FY2022 EPS estimates for shares of Molecular Partners in a note issued to investors on Wednesday
Molecular Partners AG (OTCMKTS:MLLCF) Short Interest Up 36.4% in September
Molecular Partners AG (OTCMKTS:MLLCF – Get Rating) saw a large increase in short interest in September. As of September 30th, there was short interest totalling 171,900 shares, an increase of 36.4%
Molecular Partners AG (OTCMKTS:MLLCF) Short Interest Down 6.4% in September
Molecular Partners AG (OTCMKTS:MLLCF – Get Rating) saw a large decrease in short interest during the month of September. As of September 15th, there was short interest totalling 126,000 shares, a de
Molecular Partners AG (NASDAQ:MOLN) Short Interest Down 26.4% in September
Molecular Partners AG (NASDAQ:MOLN – Get Rating) was the target of a large decrease in short interest in the month of September. As of September 15th, there was short interest totalling 19,800 shares
Analysis
Price Target
No Data
